<DOC>
	<DOC>NCT00827190</DOC>
	<brief_summary>This is a first-in-human study of ILS-920. This study will provide an initial assessment of the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ILS-920 after administration of ascending single intravenous (IV) doses to healthy adult subjects.</brief_summary>
	<brief_title>Study Evaluating Single Ascending Doses Of ILS-920</brief_title>
	<detailed_description />
	<criteria>Men or women of nonchildbearing potential Aged 18 to 50 years inclusive at screening. Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease. History of drug abuse within 1 year before study day 1.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Acute Ischemic Stroke</keyword>
</DOC>